OnKure Therapeutics, Inc. (OKUR)
| Market Cap | 227.17M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -42.12M |
| Shares Out | 13.34M |
| EPS (ttm) | -31.63 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 56,238 |
| Open | 17.10 |
| Previous Close | 17.18 |
| Day's Range | 16.75 - 17.45 |
| 52-Week Range | 9.80 - 82.90 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 37.50 (+120.2%) |
| Earnings Date | Nov 14, 2024 |
About OKUR
OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado. [Read more]
Analyst Forecast
According to 2 analysts, the average rating for OKUR stock is "Strong Buy." The 12-month stock price forecast is $37.5, which is an increase of 120.20% from the latest price.
News
OnKure: Looking To Alter PI3K Inhibitor Targeting In Breast Cancer And Beyond
Initial OnKure Therapeutics, Inc. data from the phase 1 PIKture-01 study, using OKI-219 for the treatment of patients with PI3Ka-H1047R breast cancer and solid tumors, is expected in Q4 of 2024. OKI-2...